Dr. Maha H.A. Hussain, MBChB, reviews the PROSPER trial, which tested the efficacy and safety of enzalutamide in the setting of nonmetastatic CRPC.

Keywords: PROSPER trial, enzalutamide, nonmetastatic CRPC

An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC
Summary

Dr. Maha H.A. Hussain, MBChB, provides an overview of the PROSPER trial, which tested the efficacy and safety of enzalutamide in the setting of nonmetastatic CRPC. She details the trial’s design, materials, and data.

The trial hypothesized that enzalutamide would delay metastases development in men with M0 CRPC and rapidly rising PSA. Subsequently, this would result in a delay of cancer-related morbidity and prolonged overall survival.

The trial conclusions showed that enzalutamide resulted in a clinically meaningful 71% reduction in risk of progressing to M1 CRPC, significantly delayed PSA progression, and is generally well-tolerated. While the hypothesized benefit to overall survivorship was not reached in the first interim analysis, there was a trend of 20% lower risk of death in the enzalutamide arm than the placebo arm.

Following Dr. Hussain’s presentation, she and Dr. E. David Crawford, MD, provide further discourse.